Masimo price target lowered to $153 from $200 at BTIG

BTIG analyst Marie Thibault lowered the firm’s price target on Masimo to $153 from $200 and keeps a Buy rating on the shares. Masimo’s preliminary Q2 revenue results were nearly $100M below expectations, and most of its issues are specific to the company and should not be viewed as a read-through for the broader MedTech sector, the analyst tells investors in a research note.